Risperidone

Risperidone · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 26, 2026

81 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (110)

Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 10, 2032formulationUS 10098882
Apr 10, 2032formulationUS 10098882
Apr 10, 2032formulationUS 10098882
Apr 10, 2032formulationUS 10098882
Apr 10, 2032formulationUS 10406161
Apr 10, 2032formulationUS 10406161
Apr 10, 2032formulationUS 10406161
Apr 10, 2032formulationUS 10406161
Apr 10, 2032formulationUS 11110094
Apr 10, 2032formulationUS 11110094
Apr 10, 2032formulationUS 11110094
Apr 10, 2032formulationUS 11110094
Apr 10, 2032formulationUS 9446135
Apr 10, 2032formulationUS 9446135
Apr 10, 2032formulationUS 9446135
Apr 10, 2032formulationUS 9446135
Apr 10, 2032formulationUS 9532991
Apr 10, 2032formulationUS 9532991
Apr 10, 2032formulationUS 9532991
Apr 10, 2032formulationUS 9532991
May 31, 2031formulationUS 100585044.9y
May 31, 2031formulationUS 100585044.9y
May 31, 2031formulationUS 100859364.9y
May 31, 2031formulationUS 100859364.9y
May 31, 2031method-of-use (U-3943)US 101829824.9y
May 31, 2031method-of-use (U-3943)US 101829824.9y
May 31, 2031method-of-use (U-3943)US 101951384.9y
May 31, 2031method-of-use (U-3943)US 101951384.9y
May 31, 2031formulationUS 103353664.9y
May 31, 2031formulationUS 103353664.9y
May 31, 2031formulationUS 104636074.9y
May 31, 2031formulationUS 104636074.9y
May 31, 2031formulationUS 108816054.9y
May 31, 2031formulationUS 108816054.9y
May 31, 2031method-of-use (U-3942)US 110071394.9y
May 31, 2031method-of-use (U-3942)US 110071394.9y
May 31, 2031method-of-use (U-3941)US 111731104.9y
May 31, 2031method-of-use (U-3941)US 111731104.9y
May 31, 2031method-of-use (U-3939)US 112413774.9y
May 31, 2031method-of-use (U-3939)US 112413774.9y
May 31, 2031method-of-use (U-3941)US 117520924.9y
May 31, 2031method-of-use (U-3941)US 117520924.9y
May 31, 2031formulationUS 117520934.9y
May 31, 2031formulationUS 117520934.9y
May 31, 2031method-of-use (U-3942)US 117520944.9y
May 31, 2031method-of-use (U-3942)US 117520944.9y
May 31, 2031method-of-use (U-3939)US 117594164.9y
May 31, 2031method-of-use (U-3939)US 117594164.9y
Feb 13, 2028formulationUS 100106121.6y
Feb 13, 2028formulationUS 100106121.6y
Feb 13, 2028method-of-use (U-2608)US 103765901.6y
Feb 13, 2028method-of-use (U-2608)US 103765901.6y
Feb 13, 2028formulationUS 110138091.6y
Feb 13, 2028formulationUS 110138091.6y
Feb 13, 2028method-of-use (U-3135)US 117124751.6y
Feb 13, 2028method-of-use (U-3135)US 117124751.6y
Feb 13, 2028formulationUS 91801971.6y
Feb 13, 2028formulationUS 91801971.6y
Feb 13, 2028method-of-use (U-543)US 91864131.6y
Feb 13, 2028method-of-use (U-543)US 91864131.6y
Nov 12, 2027formulationUS 82217781.4y
Nov 12, 2027formulationUS 82217781.4y
Nov 12, 2027formulationUS 82217781.4y
Nov 12, 2027formulationUS 82217781.4y
Nov 12, 2027formulationUS 82217781.4y
Nov 12, 2027formulationUS 82217781.4y
Nov 12, 2027formulationUS 82217781.4y
Nov 12, 2027formulationUS 87413271.4y
Nov 12, 2027formulationUS 87413271.4y
Nov 12, 2027formulationUS 87413271.4y
Nov 12, 2027formulationUS 87413271.4y
Nov 12, 2027formulationUS 87413271.4y
Nov 12, 2027formulationUS 87413271.4y
Nov 12, 2027formulationUS 87413271.4y
Nov 5, 2026formulationUS 11110093121d
Nov 5, 2026formulationUS 11110093121d
Sep 26, 2026method-of-use (U-2363)US 1005855481d
Sep 26, 2026method-of-use (U-2363)US 1005855481d
Sep 26, 2026formulationUS 959740281d
Sep 26, 2026formulationUS 959740281d
Jun 26, 2026formulationUS 10406160
Jun 26, 2026formulationUS 10406160

FDA exclusivities (12)

Mar 29, 2027NPNP265d
Mar 29, 2027NPNP265d
May 12, 2026CGTCGT
May 9, 2026CGTCGT
May 9, 2026CGTCGT
Apr 28, 2026NPNP
Apr 28, 2026NPNP
Apr 28, 2026

risperidone ODT

indications

all catalysts(0)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside

Patent cliff

patents (110)

FDA exclusivities (12)

Trials studying risperidone ODT